title: [Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
abstract: Gemcitabine is pyrimidine analog which has demonstrated antitumoral activity in a variety of solid tumors. Laboratory studies demonstrating that gemcitabine is a potent radiosensitizer led to a variety of trials combining radiation and gemcitabine. In the clinic, phase I-II studies are still trying to determine the optimal dose and schedule which could be use in daily clinical practice. This review summarizes the mechanisms of interaction between radiotherapy and gemcitabine and presents several therapeutic schemes for each tumor location.
authors.affiliation: Département d'oncologie-radiothérapie, CRLC Val d'Aurelle, 34298 Montpellier, France. azria@valdorel.fnclcc.fr
authors.forename: D
authors.initials: D
authors.lastname: Azria
authors.forename: M
authors.initials: M
authors.lastname: Coelho
authors.forename: C
authors.initials: C
authors.lastname: Larbouret
authors.forename: C
authors.initials: C
authors.lastname: Lemanski
authors.forename: A
authors.initials: A
authors.lastname: Serre
authors.forename: M
authors.initials: M
authors.lastname: Ychou
authors.forename: A
authors.initials: A
authors.lastname: Pèlegrin
authors.forename: J B
authors.initials: JB
authors.lastname: Dubois
authors.forename: S
authors.initials: S
authors.lastname: Culine
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine